CAS 1206799-15-6

Merestinib

Description:

Merestinib, with the CAS number 1206799-15-6, is a small molecule inhibitor primarily targeting the receptor tyrosine kinases, particularly those involved in cancer signaling pathways. It is classified as a potent inhibitor of the MET (mesenchymal-epithelial transition factor) and other related kinases, which play crucial roles in tumor growth, metastasis, and angiogenesis. Merestinib has been investigated for its potential therapeutic applications in various cancers, including non-small cell lung cancer and other solid tumors characterized by MET dysregulation. The compound exhibits a favorable pharmacokinetic profile, allowing for oral administration, and has shown promise in preclinical and clinical studies. Its mechanism of action involves blocking the phosphorylation of MET, thereby inhibiting downstream signaling pathways that contribute to cancer cell proliferation and survival. As with many targeted therapies, the efficacy of Merestinib may be influenced by the genetic and molecular characteristics of the tumor, making biomarker identification an essential aspect of its clinical application.

Synonyms:

• N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarboxamide
• MET inhibitor

N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarboxamide

CAS: 1206799-15-6

Formula: C₃₀H₂₂F₂N₆O₃

Purity: 99%

Color and Shape: Solid

Molecular weight: 552.5309

Ref: IN-DA003AMN

Merestinib

CAS: 1206799-15-6

Merestinib

Purity: ≥95%

Molecular weight: 552.53g/mol

Ref: 54-BUP07404

LY2801653

CAS: 1206799-15-6

Ref: 7W-GW3922

Merestinib

CAS: 1206799-15-6

Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.

Formula: C₃₀H₂₂F₂N₆O₃

Purity: 95% - 99.71%

Color and Shape: Solid

Molecular weight: 552.53

Ref: TM-T3455